Diagnoses in Bleeding and Thrombosis During ECMO

Diagnoses
Study Description
Bleeding and thrombosis represent major adverse events during extracorporeal membrane oxygenation (ECMO). Complications resulting from these events can lead to death or need for long term rehabilitation support. Despite the increasing use of extracorporeal support and new technology which makes it simpler and potentially safer to apply, little scientific information regarding the predictors of bleeding or thrombosis exists.

This project sought to describe the incidence of bleeding and thrombosis in ECMO patients at Collaborative Pediatric Critical Care Research Network (CPCCRN) sites and to describe current anticoagulation monitoring practices. Additionally, it sought evidence of association between bleeding and thrombotic complications, laboratory coagulation measurements, patient characteristics, ECMO circuitry, and adherence to center-specific ECMO management protocols. Data was collected on 514 subjects receiving ECMO at CPCCRN sites over a 21-month period. Data was collected on 514 subjects receiving ECMO at CPCCRN sites over a 21-month period.

诊断相关
研究概况
出血与血栓形成是体外膜肺氧合（extracorporeal membrane oxygenation, ECMO）治疗过程中最主要的不良事件。此类事件引发的并发症可导致患者死亡，或使其需要长期接受康复支持。尽管体外生命支持的应用愈发广泛，且相关新技术令操作更简便、潜在安全性有所提升，但目前针对出血或血栓形成预测因素的科学研究资料仍十分有限。

本研究旨在描述儿科重症监护协作研究网络（Collaborative Pediatric Critical Care Research Network, CPCCRN）各中心收治的ECMO患者中出血与血栓形成的发生率，并阐明当前抗凝监测的临床实践现状。此外，本研究还旨在探究出血与血栓并发症、实验室凝血检测指标、患者基线特征、ECMO循环管路设置，以及各中心对专属ECMO管理方案的依从性之间的关联证据。

本研究在21个月的周期内，从CPCCRN各中心收集了514名接受ECMO治疗患者的相关数据。本研究在21个月的周期内，从CPCCRN各中心收集了514名接受ECMO治疗患者的相关数据。